

Viracta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

SAN DIEGO, March 11, 2021 /PRNewswire/ -- [Viracta](#) Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston, President and Chief Executive Officer of Viracta will present at the Oppenheimer 31st Annual Healthcare Conference taking place virtually from March 16-18, 2021. Viracta's management team will also be available for one-on-one investor meetings at the conference.

Presentation details can be found below.

Date: Tuesday, March 16, 2021
Time: 2:30 p.m. ET
Webcast Link: <https://wswebcast.com/webcast/oppenheimer9/vira/2727098>

A replay of the presentation will be archived for 90 days on the "Events and Webcasts" section of the Viracta website at <https://viracta.investorroom.com/events-and-webcasts#past>.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569

Company Contact:

Dan Chevallard
Chief Operating Officer and Chief Financial Officer
dchevallard@viracta.com
(858) 771-4193

SOURCE Viracta

<https://viracta.investorroom.com/2021-03-11-Viracta-Therapeutics-to-Present-at-the-Oppenheimer-31st-Annual-Healthcare-Conference>